Protocol Ledger

NCT03470545 · Phase III · COMPLETED

Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Interventional Phase III clinical trial protocol NCT03470545 sponsored by Bristol Myers Squibb in Cardiovascular and Thrombosis, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-05-29 Enrollment: 251 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03470545
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)251 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03470545
Protocol FieldVerified Registry Value
NCT IdentifierNCT03470545
Consolidated Lead SponsorBristol Myers Squibb
Therapeutic Condition CohortCardiovascular and Thrombosis
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment251 participants (ACTUAL)
Registered Start Date2018-05-29
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Bristol Myers Squibb across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Cardiovascular and Thrombosis Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI